Existing Assays at Menon
Menon brings together the powers of its proprietary functionalized reagents and a wide variety of existing equipment for universal biomarker detection.
This breakthrough Molecular Mirroring ( M2 ) biosensor platform technology provides rapid, sensitive and selective detection of a wide spectrum of biomarkers from any specimen type.
Biodefense
Clinical Diagnostics
Food Safety
Our customers are commercial entities, biodefense contractors, and the government with a long track record of success (2006-2012) with the Department of Homeland Security.
Zero false alams and 100% detection.
Probes for over 20 biothreat agents verified by US govt.
External Validation for Biodefense Application
- US Department of Homeland Security
- US Defense Threat Reduction Agency
Validation for C.diff bacteria Diagnostics
- Keck School of Medicine, University of Southern California carried out independent validation experiments to detect toxigenic C. difficile from 75 patient stool specimens (Co-Principal Investigators: Drs. Pamela Ward and Rosemary She)
- Analytical sensitivity studies were conducted with 3 toxigenic C. difficile strains spiked into 3 donor stools in triplicate at varied doses
- Cross-reactivity tests were conducted to determine the analytical specificity of the assay using other Clostridium species isolated by USC as well as 2 non-toxigenic C. difficile strains. Included strains were C. sordelii, C. perfringens, and 2 non-toxigenic C. difficile strains (BAA1801 and ATCC700057). The Menon assay did not cross-react with any of the strains tested, demonstrating 100% specificity for detection of toxigenic C. difficile in clinical specimens.
- Results were presented at the ECCMID conference held in Copenhagen, Denmark, in April 2015 and published in the J. of Molecular Diagnostics.
Recent Posts
- Menon Announces Deployment of Rapid COVID-19 Test to India For Immediate Approval
- Menon Qualifies for XPRIZE Alumni Network With Molecular Mirror Platform Technology
- Escondido Scientist is Helping Mankind and Saving the Planet
- Menon Advances as Finalist in $5 Million XPRIZE Rapid COVID Testing Competition with Molecular Mirror™ Platform Technology
- Inventors Helping Inventors Podcast Interview with Suresh Menon